论文部分内容阅读
课题通过对68例急诊重症监护室(EICU)侵袭性真菌感染(IFI)患者的调研,对伊曲康唑注射液在治疗EICU患者IFI的疗效和安全性进行了分析评价。按制定的入组条件,对北京市某三甲医院EICU 2013年2月–2015年2月确诊、临床诊断和拟诊I FI患者进行筛选。使用回顾性分析法对符合条件者进行统计分析。患者年龄范围为35–90岁(平均年龄为(75.1±11.1)岁),包括36名男性和32名女性患者。全部患者抗真菌治疗有效率为60.3%,其中确诊、临床诊断和拟诊IFI患者的有效率分别为33.3%、59.5%、65.2%,其间差异有统计学意义(P<0.05)。全部患者中有11例(16.2%)出现与伊曲康唑相关的不良事件,主要表现为轻中度的肝功能受损及低血钾。伊曲康唑治疗EICU患者IFI疗效确切、安全,治疗过程中应密切关注患者肝肾功能及各生化指标,以减少不良反应的发生。
Subjects We investigated and evaluated the efficacy and safety of itraconazole in the treatment of patients with EICU in our hospital through the investigation of 68 patients with invasive fungal infections (EICU) in the intensive care unit (EICU). According to the conditions of enrollment, the patients diagnosed, clinically diagnosed and diagnosed with I FI in EICU from February 2013 to February 2015 in a top three hospital in Beijing were screened. Retrospective analysis of the use of statistical analysis of eligible persons. Patients ranged in age from 35 to 90 years (mean age, 75.1 ± 11.1 years), including 36 males and 32 females. The effective rate of antifungal therapy in all patients was 60.3%. The effective rates of diagnosed, clinically diagnosed and medically diagnosed IFI patients were 33.3%, 59.5% and 65.2%, respectively. The difference was statistically significant (P <0.05). Eleven of the patients (16.2%) had itraconazole-related adverse events, mainly manifested as mild to moderate impaired liver function and hypokalemia. Itraconazole treatment of patients with EICU IFI exact effect, safety, treatment should pay close attention to patients with liver and kidney function and biochemical indicators, in order to reduce the incidence of adverse reactions.